Mirabo Biotechnology and CMP Scientific Formulate Alliance to Enhance AI-Driven CE-MS Solutions
Mirabo Biotechnology, an innovator in artificial intelligence (AI) in biotech, has teamed up with CMP Scientific, a leader in capillary electrophoresis-mass spectrometry (CE-MS) technologies, to collaboratively develop AI-powered analytical solutions. The partnership aims to revolutionize the analysis and prediction of antibody clipping variants and post-translational modifications (PTMs), forming a cutting-edge CE-MS platform that integrates comprehensive data capabilities with advanced AI models.
On January 12, 2026, in Brooklyn, NY, the two organizations announced their strategic alliance to create an automated CE-MS analytical solution that aligns Mirabo’s proprietary MiRAiQ™ AI engine with CMP’s extensive CE-MS expertise. This collaboration is set to launch an unparalleled closed-loop service, which spans from precise detection to AI-enhanced molecular redesign, effectively addressing significant challenges in biologics research and development (R&D).
Key Highlights of the Partnership:
- Innovative Software Development: The partnership will produce two interoperable software tools, one focused on CE-MS data analysis and the other on AI predictions.
- Streamlined Process: This integration will automate the pipeline from raw CE-MS data to actionable biological insights, enhancing the accuracy and speed of antibody variant assessments.
- Holistic R&D Solutions: The collaboration promises a comprehensive approach to biologics development, enhancing production readiness and quality control through integrated analytics.
Mirabo’s advanced AI models aim to identify potential variant risks and PTM profiles early in the development process, significantly reducing costs and associated risks. Meanwhile, CMP’s established capabilities in CE-MS will deliver high-precision insights, enriching the analytical landscape for biopharma companies.
This strategic partnership embodies a significant leap forward in the integration of AI within the biopharmaceutical workflow, aspiring to enhance the future of biologics development and help deliver life-saving therapies more efficiently and effectively. Both companies are committed to ongoing collaboration aimed at advancing technology and expanding their suite of services across various biopharmaceutical modalities.
For more information about Mirabo Biotechnology and CMP Scientific, please visit their respective websites.
